|
|
|
|
| LEADER |
04973nam a2200517 4500 |
| 001 |
ocn863823787 |
| 003 |
OCoLC |
| 005 |
20180501122014.0 |
| 006 |
m o d |
| 007 |
cr |n||||||||| |
| 008 |
131123s2014 vtu o 000 0 eng d |
| 040 |
|
|
|a EBLCP
|b eng
|e pn
|c EBLCP
|d OCLCQ
|d TEF
|d N$T
|d OCLCF
|d OHS
|d OCLCQ
|d DEBSZ
|d OCLCQ
|d DEBBG
|d MEU
|d OCLCQ
|d GrThAP
|
| 019 |
|
|
|a 1028553655
|
| 020 |
|
|
|a 9780124202115
|q (electronic bk.)
|
| 020 |
|
|
|a 012420211X
|q (electronic bk.)
|
| 020 |
|
|
|a 0124201466
|
| 020 |
|
|
|a 9780124201460
|
| 035 |
|
|
|a (OCoLC)863823787
|z (OCoLC)1028553655
|
| 050 |
|
4 |
|a QP552.G16
|
| 072 |
|
7 |
|a SCI
|x 007000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 572.6
|2 23
|
| 049 |
|
|
|a TEFA
|
| 245 |
0 |
0 |
|a Inhibitors of the Ras Superfamily G-proteins.
|n Part B /
|c edited by Fuyuhiko Tamanoi, Channing J. Der.
|
| 260 |
|
|
|a Burlington :
|b Elsevier Science,
|c 2014.
|
| 300 |
|
|
|a 1 online resource (275 pages)
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 505 |
0 |
|
|a Front Cover; Inhibitors of the Ras Superfamily G-proteins, Part B; Copyright; Contents; Preface; Chapter One: Discovery of Small-Molecule Ras Inhibitors that Display Antitumor Activity by Interfering with Ras. GTP-Effec ... ; 1. Introduction; 2. Discovery of Surface Pockets in Novel Crystal Structures of Ras. GTP; 3. Discovery of the Kobe0065-Family Compounds by In Silico Screening; 4. Inhibition of Ras Functions by the Kobe0065-Family Compounds; 4.1. Inhibition of Ras-Effector interaction; 4.2. Inhibition of proliferation of cultured cancer cells.
|
| 505 |
8 |
|
|a 4.3. Inhibition of tumor growth in a xenograft model5. Structural Basis for Inhibition of Ras Functions by the Kobe0065-Family Compounds; 6. Specificity of the Kobe0065-Family Compounds Toward Various Small GTPases; 7. Discussion and Conclusion; Acknowledgments; References; Chapter Two: An Orthosteric Inhibitor of the RAS-SOS Interaction; 1. Introduction; 2. RAS Signaling in Normal Physiology and Malignancy; 3. Strategies for Targeting RAS Activity; 4. Inhibitor Design; 5. RAS Binding; 6. Cell Entry and Intracellular Effects; 7. Conclusions; References.
|
| 505 |
8 |
|
|a Chapter Three: Conformation-Specific Inhibitors of Raf Kinases1. Introduction; 2. Kinase Conformations and Different Types of Kinase Inhibitors; 3. Representative Raf Inhibitors and Their Binding Modes; 4. Raf Kinase Dimerization and Activation; 5. Perspective; 6. Conclusion; Acknowledgments; References; Chapter Four: Inhibitors of the ERK Mitogen-Activated Protein Kinase Cascade for Targeting RAS Mutant Cancers; 1. Introduction; 2. Ras and the ERK MAPK Effector Signaling Network; 2.1. H-Ras, K-Ras4A/4B, and N-Ras; 2.2. A-Raf, B-Raf, and C-Raf/Raf-1; 2.3. MEK1 and MEK2; 2.4. ERK1 and ERK2.
|
| 505 |
8 |
|
|a 3. Role of the ERK MAPK Cascade in Mutant RAS-Dependent Tumor Progression and Maintenance4. MEK1/2 Inhibitors; 4.1. Trametinib; 4.2. Selumetinib; 4.3. Pimasertib; 4.4. Cobimetinib; 4.5. PD0325901; 4.6. Refametinib; 4.7. AZD8330; 4.8. TAK-733; 4.9. MEK162; 4.10. RO5126766; 4.11. RO4987655; 4.12. E6201; 5. ERK1/2 Inhibitors; 5.1. SCH772984; 5.2. MK-8353/SCH900353; 5.3. BVD-523; 5.4. VTX11e; 5.5. AEZS-131/AEZS-134; 5.6. FR180204; 6. Issues and Questions; Acknowledgments; References; Chapter Five: Inhibiting the RAS-PI3K Pathway in Cancer Therapy; 1. Introduction; 2. The PI3K Pathway.
|
| 505 |
8 |
|
|a 3. PI3K Inhibitors4. PI3K Pathway Inhibitors; 5. Inhibiting PI3K in Cancer; 6. Future Directions; References; Chapter Six: The RalGEF/Ral Pathway: Evaluating an Intervention Opportunity for Ras Cancers; 1. Introduction; 1.1. Oncogenic Ras signaling: Targeting troubles prompt alternative approaches; 1.2. RalGEF/Ral pathway overview; 1.2.1. RalGEFs; 1.2.2. Ral GTPases and their effectors; 1.2.3. RalGAPs; 2. RalGEF/Ral Signaling and Cancer: A Rationale for Pathway Inhibition; 2.1. Evidence from tumor cell models; 2.2. Evidence from genetically engineered mouse models.
|
| 500 |
|
|
|a 2.3. Evidence from clinical correlates.
|
| 520 |
|
|
|a Targeted toward researchers in biochemistry, molecular and cell biology, pharmacology, and cancer, this is the second part of The Enzymes' volumes that discuss inhibitors of the Ras superfamily G-proteins. Key features: Contributions from leading authorities, Informs and updates on all the latest developments in the field.
|
| 588 |
0 |
|
|a Print version record.
|
| 546 |
|
|
|a Text in English.
|
| 650 |
|
0 |
|a Ras proteins.
|
| 650 |
|
7 |
|a SCIENCE
|x Life Sciences
|x Biochemistry.
|2 bisacsh
|
| 650 |
|
7 |
|a Ras proteins.
|2 fast
|0 (OCoLC)fst01090194
|
| 655 |
|
4 |
|a Electronic books.
|
| 700 |
1 |
|
|a Tamanoi, Fuyuhiko.
|
| 700 |
1 |
|
|a Der, Channing J.
|
| 776 |
0 |
8 |
|i Print version:
|a Tamanoi, Fuyuhiko.
|t Inhibitors of the Ras Superfamily G-proteins, Part B.
|d Burlington : Elsevier Science, ©2014
|z 9780124201460
|
| 830 |
|
0 |
|a Enzymes ;
|v v. 34.
|
| 856 |
4 |
0 |
|u https://www.sciencedirect.com/science/bookseries/18746047/34
|z Full Text via HEAL-Link
|
